FDA officials recently announced the availability of draft guidance on the nonproprietary naming of biological products, calling it a key issue for ensuring their safety and promoting their acceptance.
Powered by Börsen-Handelssysteme
AAO News Archive
- Deal struck to develop integrin antagonist treatment
- New low-add multifocal IOLs yield higher patient satisfaction
- Regeneron, Bayer to develop AMD combination therapy
- FDA approves wide-field imaging system for newborns
- Brain mapping may someday lead to vision-restoring therapies
- FDA warns of loose safety seals on eye drops
- Stem cells regrow human lens, corneal tissue
FDA issues draft guidance on nonproprietary naming of biologics, biosimilars
- Details